(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of -0.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Mimedx Group's revenue in 2026 is $355,173,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $40,085,586,305, with the lowest MDXG revenue forecast at $37,139,767,246, and the highest MDXG revenue forecast at $42,088,335,135. On average, 7 Wall Street analysts forecast MDXG's revenue for 2027 to be $45,066,221,496, with the lowest MDXG revenue forecast at $41,454,277,099, and the highest MDXG revenue forecast at $48,318,137,537.
In 2028, MDXG is forecast to generate $50,771,286,214 in revenue, with the lowest revenue forecast at $47,994,549,298 and the highest revenue forecast at $53,107,826,516.